A Novel Immortalized Human Adrenal Cell Line with Inactive Protein Kinase A for Studies on cAMP Signaling and Endocrine Tumorige
Posted Sep 27 2012 8:00pm
Description of Invention: The first known immortalized cell line with a naturally-occurring inactivating mutation in PRKAR1A, the regulatory subunit type 1A (R1alpha) of protein kinase A (PKA), which is associated with tumor formation.
PKA isozyme balance is critical for the control of cAMP signaling and related cell cycle and proliferation changes. Aberrant cAMP signaling has been linked to adrenocortical and other, mostly endocrine, tumors. Inactivating mutations in the PRKAR1A gene are a known cause of Carney Complex - an autosomal dominant multiple neoplasia syndrome associated with skin, heart, and other myxomas and a variety of endocrine tumors.
Studies on multiple tumor formation associated with Carney Complex.
Characterization of cAMP-mediated mechanisms of endocrine tumor formation.
Studies of a large variety of cAMP-mediated processes in normal physiology and disease.
Advantages: First known immortalized cell line with a naturally-occurring inactivating mutation in the PRKAR1A gene.
Development Status: In vitro data available
Inventors: Constantine A Stratakis (NICHD)
Patent Status: HHS, Reference No. E-267-2012/0
Research Material — Patent protection is not being pursued for this technology.
Collaborative Research Opportunity: The Eunice Kennedy Shriver National Institute of Child Health and Human Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Joseph Conrad III, Ph.D. at email@example.com .
For Licensing Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220